Viewing Study NCT06055881



Ignite Creation Date: 2024-05-06 @ 7:33 PM
Last Modification Date: 2024-10-26 @ 3:09 PM
Study NCT ID: NCT06055881
Status: RECRUITING
Last Update Posted: 2023-10-26
First Post: 2023-09-20

Brief Title: Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy BOSS
Sponsor: Mayo Clinic
Organization: Mayo Clinic

Study Overview

Official Title: Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy BOSS
Status: RECRUITING
Status Verified Date: 2023-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study assesses if metastasis-directed radiation therapy Stereotactic body radiation therapy - SBRT can delay a change in systemic therapy and if circulating tumor cells in the bloodstream can help guide treatment options in metastatic breast cancer patients with progressive disease
Detailed Description: PRIMARY OBJECTIVE

I To assess whether radiotherapy can provide clinically significant freedom from a change in systemic therapy defined as for at least 6 months for well-selected patients with oligoprogressive metastatic breast cancer

OUTLINE This is an observational study

Patients undergo blood sample collection and complete questionnaires on study

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
NCI-2023-03208 REGISTRY None None
22-002943 OTHER None None
GMROR2232 OTHER Mayo Clinic Radiation Oncology None